Homer Pearce Aug 09, 2007 Premium Save for later Kylin Therapeutics this week said it has appointed Homer Pearce to its board of directors. Pearce was previously vice president of cancer research and clinical investigation at Eli Lilly. He holds a PhD in chemistry from Harvard University. Filed under Gene Silencing/Gene Editing RNAi Breaking News Cytosine Base Editor Enables Genome-Wide Genetic Function Screening G42 Healthcare, Seegene to Offer Mobile Molecular Diagnostic Labs in Middle East, North Africa JP Morgan, Cowen Initiate Coverage of Singular Genomics Systems Top Five Articles on GenomeWeb Last Week: Danaher, Becton Dickinson, 23andMe, and More Berry Oncology, Alibaba Health Partner to Offer Early Cancer Screening, Health Services Roche Receives FDA EUA for PCR-Based, Point-of-Care SARS-CoV-2 Test The Scan Renewed Gain-of-Function Worries The New York Times writes that the pandemic is renewing concerns about gain-of-function research. Who's Getting the Patents? A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports. Other Uses CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2. PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.